PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29533074-1 2018 Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 0-20 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 29533074-1 2018 Rosuvastatin calcium (ROS), ( Figure 1 ) belongs to the "statins" group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 22-25 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 86-143 29692602-1 2018 Purpose: Rosuvastatin is a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor that effectively reduces low-density lipoprotein cholesterol levels. Rosuvastatin Calcium 9-21 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-84 27941393-3 2017 We performed a pilot study of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin to determine effects on lung function. Rosuvastatin Calcium 92-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-81 25719441-1 2016 The current study aimed at the evaluation of, in vivo, the effect of omeprazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 107-119 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 123-180 26930419-1 2016 Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 148-195 26908399-4 2016 In vitro, activator protein 1 activity was inhibited by two 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, rosuvastatin and atorvastatin, in stretch-stimulated human venous smooth muscle cells. Rosuvastatin Calcium 120-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 60-107 26093357-1 2015 Rosuvastatin (RST), a synthetic statin, is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, with a number of pleiotropic properties, such as anti-inflammation, antioxidation and cardiac remodelling attenuation. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 26093357-1 2015 Rosuvastatin (RST), a synthetic statin, is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, with a number of pleiotropic properties, such as anti-inflammation, antioxidation and cardiac remodelling attenuation. Rosuvastatin Calcium 14-17 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 45-92 26081159-1 2015 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor used to lower blood low-density lipoprotein cholesterol, is a substrate of the membrane ABCG2 exporter. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-63 25767372-1 2015 PURPOSE: Valsartan, an angiotensin-receptor blocker, and rosuvastatin, a competitive inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, are frequently coadministered to treat patients with hypertension and dyslipidemia. Rosuvastatin Calcium 57-69 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-149 25453767-0 2015 HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS. Rosuvastatin Calcium 28-40 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 0-17 25453767-10 2015 Here, we provide evidence that among HMG-CoA reductase inhibitors, rosuvastatin was the most effective statin on the reduction of epileptiform activity, which was associated with improved BBB permeability, increased expression of eNOS and decreased expressions of pro-apoptotic p53, Bax and caspase-3. Rosuvastatin Calcium 67-79 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 26411232-1 2015 The authors report a case of transient azoospermia following hydroxymethylglutaryl-coenzyme A reductase (HMGCR) inhibitor rosuvastatin medication for hypercholesterolemia. Rosuvastatin Calcium 122-134 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 61-103 26411232-1 2015 The authors report a case of transient azoospermia following hydroxymethylglutaryl-coenzyme A reductase (HMGCR) inhibitor rosuvastatin medication for hypercholesterolemia. Rosuvastatin Calcium 122-134 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 105-110 25128668-5 2014 An estimate of the binding energy between rosuvastatin and HMGCR has been made using: (a) a coulombic electrostatic interaction model, (b) the calculated desolvation and resolvation of the statin in water, and (c) the first shell transfer solvation energy as a proxy for the restructuring of the water molecules immediately adjacent to the active binding site of HMGCR prior to binding. Rosuvastatin Calcium 42-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 59-64 25128668-5 2014 An estimate of the binding energy between rosuvastatin and HMGCR has been made using: (a) a coulombic electrostatic interaction model, (b) the calculated desolvation and resolvation of the statin in water, and (c) the first shell transfer solvation energy as a proxy for the restructuring of the water molecules immediately adjacent to the active binding site of HMGCR prior to binding. Rosuvastatin Calcium 42-54 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 363-368 24137286-2 2013 Rosuvastatin, a selective inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, has pharmacological properties including the ability to reduce low-density lipoprotein-cholesterol (LDL-C) and very low-density lipoprotein-cholesterol (VLDL-C) levels, slow atherosclerosis progression and improve coronary heart disease outcomes. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 39-91 23256625-2 2013 This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin. Rosuvastatin Calcium 147-159 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 102-119 23447089-1 2013 Rosuvastatin is a highly effective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is used for the treatment of patients with hyperlipidemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-105 22442638-1 2012 Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-50 21881526-14 2011 This effect, partially amplified in the presence of high glucose and FFA, is reversed by rosuvastatin, suggesting another potential therapeutic application for this 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. Rosuvastatin Calcium 89-101 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 165-212 20653359-10 2010 Evidence demonstrates that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy (i.e., atorvastatin and rosuvastatin) significantly reduces surrogate cardiovascular markers, particularly LDL, in patients with ESRD requiring hemodialysis; however, no statin has proved to reduce cardiovascular morbidity or mortality in this population. Rosuvastatin Calcium 126-138 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-74 19956889-4 2010 In addition, modulation of drug-induced cytotoxicity by the free radical scavenger amifostine, the low molecular weight heparin dalteparin, the iron-chelator dexrazoxane, the HMG-CoA reductase inhibitor rosuvastatin and the PPAR agonist troglitazone was tested. Rosuvastatin Calcium 203-215 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 175-192 21701608-1 2009 Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 48-105 18177480-0 2008 In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Rosuvastatin Calcium 120-132 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 62-109 18355422-1 2008 OBJECTIVE: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used for the treatment of dyslipidaemia, may be co-administered with antacids in clinical practice. Rosuvastatin Calcium 11-23 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 27-84 17692320-0 2008 The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Rosuvastatin Calcium 32-44 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 4-21 17577102-1 2007 BACKGROUND: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects that are anti-inflammatory and antiatherothrombotic. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-75 16581327-1 2006 The adverse event (AE) profiles of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) agents are of great interest, in particular the most recently approved statin, rosuvastatin. Rosuvastatin Calcium 191-203 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 35-92 16144509-2 2005 Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is the most efficacious lipid-lowering agent of the statin class. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 16-63 16128507-1 2005 OBJECTIVE: To summarize the relevant pharmacologic, clinical, and safety data regarding rosuvastatin (Crestor--AstraZeneca), the most recently marketed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor approved for the treatment of dyslipidemia. Rosuvastatin Calcium 88-100 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 152-209 15137986-1 2004 A selective, accurate and precise assay was developed for the quantification in human plasma of the N-desmethyl metabolite of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor rosuvastatin. Rosuvastatin Calcium 198-210 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 130-187 14983742-7 2003 Rosuvastatin, a recently marketed inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A reductase, is an effective drug which may normalize high plasma cholesterol among high-risk subjects more often than other similar molecules, thus permitting to reach stringent guideline lipid targets. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 51-98 14983747-1 2003 Rosuvastatin is a new statin with a great number of pharmacological benefits related to the capacity of modifying favorably the lipid profile but also for the selective binding with 3-hydroxy-3-methylglutaryl coenzyme A reductase, relative hydrophilic properties and selectivity for hepatic cells. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 182-229 14693307-1 2003 BACKGROUND: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, or statin, that has been developed for the treatment of dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 15030249-0 2003 Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 33-50 15030249-2 2003 Relative to other statins, rosuvastatin possesses a greater number of binding interactions with HMG-CoA reductase and has a high affinity for the active site of the enzyme. Rosuvastatin Calcium 27-39 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 96-113 14667956-1 2003 BACKGROUND: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor developed for the treatment of dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 30-77 14512129-1 2003 BACKGROUND: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has been developed for the treatment of patients with dyslipidemia. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 28-75 12773150-0 2003 Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Rosuvastatin Calcium 92-104 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 38-88 12682802-1 2003 RATIONALE OBJECTIVE: To examine in vivo the effect of erythromycin on the pharmacokinetics of rosuvastatin [an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase]. Rosuvastatin Calcium 94-106 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 124-181 12709722-1 2003 BACKGROUND: Rosuvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 34-91 12534645-1 2003 AIMS: To examine in vivo the effect of ketoconazole on the pharmacokinetics of rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Rosuvastatin Calcium 79-91 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 95-152 12824720-1 2003 Rosuvastatin (Crestor; licensed to AstraZeneca, Macclesfield, UK from Shionogi, Osaka, Japan) is a new statin with pharmacologic characteristics that translate into selectivity of effect in hepatic cells and enhanced potency in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 228-275 12445025-1 2002 AIMS: To compare the lipid-regulating effects and steady-state pharmacokinetics of rosuvastatin, a new synthetic hydroxy methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, following repeated morning and evening administration in volunteers with fasting serum low-density lipoprotein cholesterol (LDL-C) concentrations < 4.14 mmol l-1. Rosuvastatin Calcium 83-95 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 113-166 12769127-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 12481202-0 2002 Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 37-54 12481202-1 2002 Rosuvastatin, a new statin, has been shown to possess a number of advantageous pharmacological properties, including enhanced HMG-CoA reductase binding characteristics, relative hydrophilicity, and selective uptake into/activity in hepatic cells. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 126-143 12269853-1 2002 Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 18-70 11772327-2 2002 Rosuvastatin, like atorvastatin, has a plasma half-life of about 20 h and is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 99-156 33428168-1 2021 BACKGROUND: Rosuvastatin is a lipid-lowering drug that works by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme responsible for producing cholesterol in humans. Rosuvastatin Calcium 12-24 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 75-122 30942448-8 2019 We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Rosuvastatin Calcium 26-38 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 209-249 30942448-8 2019 We also demonstrated that rosuvastatin potentiated the effects of mitotane by reducing cell viability, inducing apoptosis, increasing intracellular free cholesterol levels, and by decreasing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP binding cassette subfamily a member 1 (ABCA1), genes involved in cholesterol metabolism, and inhibiting steroidogenesis. Rosuvastatin Calcium 26-38 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 251-256 30290001-1 2019 Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, and one of the most popular antihyperlipidemic medications have been found to possess pharmacodynamic activities much different from its usual indication. Rosuvastatin Calcium 0-12 3-hydroxy-3-methylglutaryl-CoA reductase Homo sapiens 53-71